All Posts
  • Press Releases
1 min read

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

On this page

Share

First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional safety, accelerated immune reconstitution, and dose-dependent persistence and induction of Tr1 and FOXP3+ regulatory T cells. All patients achieved successful engraftment and donor chimerism following transplantation.

Related Articles

Explore posts connected to this topic

View Resources

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

  • Interviews

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos

Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles

Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos

In a clinical first, Tr1X Bio showed immune reconstitution and

  • Interviews

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos
Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos